OCTP update from Doceo
Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video content with Doceo.
Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market, is pleased to announce a new video on Doceo.
OCT is a dynamic biotechnology company aiming to revolutionise drug development by utilising a diverse range of compounds, including proprietary cannabinoid derivatives, natural phytocannabinoids, and innovative new chemical entities (NCEs) that target the endocannabinoid system. Their strategic approach ensures the creation of a drug development portfolio that maximises the therapeutic potential of cannabinoids, while also driving long-term market value and market exclusivity in all activities.
For an update on OCT, visit: https://doceo.tv/funds/oxford-cannabinoid-technologies/. For further information on Doceo please visit www.doceo.tv or contact the team on info@doceo.tv
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 6 hours ago Luceco
- 6 hours ago Legal & General Group
- 6 hours ago Downing Renewables & Infrastructure Trust
- 7 hours ago Henderson Far East Income Ltd.
- 7 hours ago Whitbread